While <i>RET</i> fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with <i>TRIM33-RET</i> fusion has not been previously reported. The gene discussed is RET; the disease is pancreatic neoplasm.